Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The onset of the therapeutic response to antidepressant treatment exhibits a characteristic delay. Animal models sensitive to chronic, but not acute, antidepressant treatment are greatly needed for studying antidepressant mechanisms. We initially assessed four inbred mouse strains for their behavioral response to chronic treatment with the selective-serotonin reuptake inhibitor fluoxetine (0, 5, 10 mg/kg/day in drinking water), which is used for the treatment of mood and anxiety disorders. Only the highly anxious BALB/c strain exhibited sensitivity to fluoxetine in the forced swim test. Additionally, fluoxetine reduced locomotion in C57BL/6 and 129SvEv, but not BALB/c and DBA/2, strains. We then evaluated the effects of subchronic (approximately 4 days) and chronic (approximately 24 days) fluoxetine treatment (0, 10, 18, 25 mg/kg/day) on measures of anxiety and depression in BALB/c mice. Anxiety measures were obtained using the open field and novelty-induced hypophagia tests. Antidepressant effects were evaluated using the forced swim test. We found 18 mg/kg/day of chronic fluoxetine to be active in all three paradigms; subchronic treatment had no effect. Anxiety-related measures were reduced by 18 mg/kg/day. In the forced swim test, 10 and 18 mg/kg/day increased swimming and reduced immobility. Here we present several novel effects of chronic, but not subchronic, antidepressant treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This dosage of 18 mg/kg/day have been shown to be in the upper range of the therapeutic dose of fluoxetine administered to humans.16”
From Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression (2025) · cites this paper as [16]
In the citing paper
“Hyponeophagia (novelty-suppressed feeding) has also been used to assess anxiety-like behavior in rodents; in a novel environment, hungry mice exhibit an increased latency to feed that is sensitive to benzodiazepines and SSRIs47,48.”
From Resolving the neural circuits of anxiety (2015) · cites this paper as [47]
In the citing paper
“The NIH paradigm is a sensitive measure for potential anxiolytic drugs and anxiogenic effects of withdrawal on both acute and extended drug administration paradigms (Dulawa et al., 2004;Dulawa and Hen, 2005).”
From Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors (2014) · cites this paper as Dulawa et al., 2004
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“We have previously shown that steady state for both fluoxetine and norfluoxetine is achieved by 5 days of receiving fluoxetine in the drinking water (10 mgskgsday), as serum levels after 5 or 90 days of treatment are equivalent (”
BackgroundSelf-citationBehavioral despair in mice: a primary screening test for antidepressants.
Porsolt, R. D., Bertin, A., & Jalfre, M. (1977) · PubMed · Cited by 4,013
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review
Prut, L., & Belzung, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01272-x · Cited by 3,175
Willner, P. (1997) · Psychopharmacology · doi:10.1007/s002130050456 · Cited by 1,832 · cited 1×
“The intake of palatable fluids, including sucrose and saccharin solutions, has been used as a measure of reward sensitivity (”
MethodAssessing antidepressant activity in rodents: recent developments and future needs
Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551
Psychopharmacology: The Fourth Generation of Progress
Green, A. I. (1996) · Psychiatric Services · doi:10.1176/ps.47.3.312 · Cited by 1,145
Neuropsychopharmacology: The Fifth Generation of Progress
SAGDUYU, K. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1251-a · Cited by 1,019
Pharmacokinetics of selective serotonin reuptake inhibitors
Hiemke, C., & Härtter, S. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(99)00048-0 · Cited by 883
Antidepressants and neuroplasticity
D'Sa, C., & Duman, R. S. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01203.x · Cited by 513 · cited 1×
“These long-term effects are thought to involve increases in neural plasticity and growth-related events (”
Background
Research works printed but not linked: 2
- Hirschfeld R, Weisssman M (2002). Risk factors for major depression and bipolar disorder. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 1018–1025.
- Merikangas K, Pine D (2002). Genetic and other vulnerability factors for anxiety and stress disorders. In: Davis K, Charney D, Coyle J, Nemeroff C (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: Philadelphia. pp 868–882.
Cited by
Items 301–400 of 693
Tamburella, A., Micale, V., Leggio, G. M., & Drago, F. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.04.006 · Cited by 37
“It is commonly believed that the FST procedure shows specific sensitivity to the acute antidepressant treatment; in our experiments it was also sensitive to a repeated treatment, according to previous studies (Rénéric et al., 2002; Dulawa et al., 2004; Cryan et al., 2005; Micale et al., 2008a).”
McEuen, J. G., Semsar, K. A., Lim, M. A., & Bale, T. L. (2009) · Endocrinology · doi:10.1210/en.2008-1721 · Cited by 36
“In behavioral testing, responses were measured in mice after 4 wk citalopram (35).”
MethodAnxiolytic-like actions of reboxetine, venlafaxine and endurance swimming in stressed male rats
Lapmanee, S., Charoenphandhu, N., Krishnamra, N., & Charoenphandhu, J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.02.037 · Cited by 38
Intervention in the Context of Development: Pathways Toward New Treatments
Veenstra-VanderWeele, J., & Warren, Z. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.232 · Cited by 34
“In contrast, studies of serotonin reuptake inhibitors in mouse and human reveal effects of chronic treatment emerging only after 3–6 weeks, suggesting similar patterns of receptor accommodation over time across species (Dulawa et al, 2004).”
ResultAntidepressants differentially modify the extinction of an aversive memory task in female rats
Melo, T. G., Izídio, G. S., Ferreira, L. S., Sousa, D. S., Macêdo, P. T., Cabral, A., Ribeiro, A. M., & Silva, R. H. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.01.012 · Cited by 35
Party, H., Dujarrier, C., Hébert, M., Lenoir, S., de Lizarrondo, S. M., Delépée, R., Fauchon, C., Bouton, M., Obiang, P., Godefroy, O., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0807-2 · Cited by 35
Pagliusi, M., Bonet, I. J. M., Brandão, A. D. F., de Magalhães, S. F., Tambeli, C. H., Parada, C. A., & Sartori, C. R. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2019.12.037 · Cited by 37
Dimitrov, M., Nikolova, I., Benbasat, N., Kitanov, G., & Danchev, N. (2011) · Biotechnology & Biotechnological Equipment · doi:10.5504/bbeq.2011.0099 · Cited by 32
Saleh, L. A., Hamza, M., Gayar, N. H. E., El-Samad, A. A. A., Nasr, E. A., & Masoud, S. I. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.07.013 · Cited by 38
Conley, R. K., & Hutson, P. H. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.02.063 · Cited by 35
Lutz, P. E., Reiss, D., Ouagazzal, A. M., & Kieffer, B. L. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.049 · Cited by 32
“Previous studies comparing Balb and Bl6J mice failed to detect increased levels of behavioural despair in Balb mice in the FS [64], and found no change [65] or a small increase [66] in the TS.”
BackgroundBentea, E., Demuyser, T., Liefferinge, J. V., Albertini, G., Deneyer, L., Nys, J., Merckx, E., Michotte, Y. M., Sato, H., Arckens, L., et al. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.01.010 · Cited by 36
Gardier, A. M., Guiard, B. P., Guilloux, J., Repérant, C., Coudoré, F., & David, D. J. P. (2009) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00640.x · Cited by 40
“, 1985) [13] • Anxiolytic-like activity: – Elevated plus maze – Open field paradigm (Dulawa et al., 2004) [14] – Black and White box – Stress-induced hyperthermia • Mixed antidepressant/anxiolytic-like activity: – Novelty suppressed feeding (David et al.”
BackgroundHo, E. V., Thompson, S. L., Katzka, W. R., Sharifi, M. F., Knowles, J. A., & Dulawa, S. C. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4086-8 · Cited by 34
“However, chronic fluoxetine has not been found to affect center activity measures on various mouse strains, including C57Bl/6J (Dulawa et al. 2004).”
BackgroundMethodSelf-citationPalumbo, M. L., Zorrilla Zubilete, M. A., Cremaschi, G. A., & Genaro, A. M. (2009) · Stress · doi:10.1080/10253890802506383 · Cited by 30
“…is considered a non-emotive, nonanxiogenic and active strain in different experimental situations, such as the open-field test or the elevated plus-maze test (Tassin et al. 1980; Marona-Lewicka and Vetulani 1989; Lepicard et al. 2000; Belzung and Griebel 2001; Tang et al. 2002, Dulawa et al. 2004).”
BackgroundDo Selective Serotonin Reuptake Inhibitors (SSRIs) Cause Fractures?
Warden, S. J., & Fuchs, R. K. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0322-3 · Cited by 34
Vahid-Ansari, F., & Albert, P. R. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0590-3 · Cited by 34
“tration as described [25], and exercise was free RW with FW as control.”
Validation of hippocampal biomarkers of cumulative affective experience
Poirier, C., Bateson, M., Gualtieri, F., Armstrong, E. A., Laws, G. C., Boswell, T., & Smulders, T. V. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.03.024 · Cited by 35
“These tests have been validated using drugs shown to have clinical efficacy in 203 treating human mood disorders (Christmas and Maxwell, 1970; Dulawa et al., 2004; Merali et 204 al., 2003; Pellow et al., 1985; Pellow and File, 1986; Wallace-Boone et al., 2008).”
Inaba, H., Li, H., Kawatake-Kuno, A., Dewa, K., Nagai, J., Oishi, N., Murai, T., & Uchida, S. (2023) · Science Advances · doi:10.1126/sciadv.ade5397 · Cited by 33
Nashed, M. G., Ungard, R. G., Young, K., Zacal, N., Seidlitz, E. P., Fazzari, J., Frey, B. N., & Singh, G. (2017) · Scientific Reports · doi:10.1038/srep41382 · Cited by 35
Kim, H., Choi, H., Han, K., Sim, W., Suh, H. J., & Ahn, Y. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119224 · Cited by 32
Woehrle, N. S., Klenotich, S. J., Jamnia, N., Ho, E. V., & Dulawa, S. C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2985-0 · Cited by 32
“Fluoxetine was administered in the drinking water at a concentration of 80 mg/L to achieve a 10- mg/kg/day dose (Dulawa et al. 2004).”
MethodSelf-citationHenze, M., Tiniakov, R. L., Samarel, A. M., HOLMES, E. W., & Scrogin, K. E. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00763.2012 · Cited by 31
Frick, L. R., Rapanelli, M., Arcos, M. L. B., Cremaschi, G., & Genaro, A. M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.03.037 · Cited by 32
Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression
Bowman, M. A., & Daws, L. C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00156 · Cited by 30
Genetic dissection of intermale aggressive behavior in BALB/cJ and A/J mice
Dow, H. C., Kreibich, A. S., Kaercher, K. A., Sankoorikal, G. M. V., Pauley, E. D., Lohoff, F. W., Ferraro, T. N., Li, H., & Brodkin, E. S. (2010) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2010.00640.x · Cited by 33
“…Ltd and International Behavioural and Neural Genetics Society et al. 2001; Crowley et al. 2006; Dougherty et al. 2004; Ducottet & Belzung 2005; Dulawa et al. 2004; Fairless et al. 2008; Guillot & Chapouthier 1996; Jensen et al. 2007; Jones & Brain 1987; Kessler et al. 1977; McCracken et…”
Dantec, Y. L., Hache, G., Guilloux, J., Guiard, B. P., David, D. J. P., Adrien, J., & Escourrou, P. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.050 · Cited by 32
“This behavioral test characterizes anxiety-like behavior (Prut and Belzung, 2003; Dulawa et al., 2004; David et al., 2009).”
(R)-fluoxetine enhances cognitive flexibility and hippocampal cell proliferation in mice
Marwari, S., & Dawe, G. S. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754733 · Cited by 31
“This protocol of chronic administration of fluoxetine to adult mice has been reported to result in clinically relevant plasma levels (Dulawa et al., 2004; Rantamaki et al., 2007) and to effectively produce behavioral alternations in depression and anxiety-like behaviors (Karpova et al.”
BackgroundFluoxetine induces paradoxical effects in C57BL6/J mice: comparison with BALB/c mice
Gosselin, T., Guisquet, A. L., Brizard, B., Hommet, C., Minier, F., & Belzung, C. (2017) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000321 · Cited by 32
“This procedure consists of the application of daily mild stressors to induce depressive-like behaviours in mice; these effects are prevented by chronic treatment with antidepressants such as FLX (Dulawa et al., 2004; Surget et al., 2011).”
BackgroundPham, T. H., Defaix, C., Nguyen, T. M. L., Mendez‐David, I., Tritschler, L., David, D. J. P., & Gardier, A. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172913 · Cited by 30
Gall, J. I., Alves, A. G., Júnior, L. R. C., Rech, T. D. S. T., Neto, J. S. S., Alves, D. A. C., Soares, M. S. P., Spohr, L., Spanevello, R. M., Brüning, C. A., et al. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109956 · Cited by 32
Manning, E. E., Geramita, M. A., Piantadosi, S. C., Pierson, J. L., & Ahmari, S. E. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.11.018 · Cited by 32
Evsiukova, V. S., Базовкина, Д. В., Bazhenova, E., Kulikova, E. A., & Kulikov, A. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312851 · Cited by 30
“It needs to emphasize that chronic treatment with fluoxetine also decreases anxiety in mice in the open field test [45,46].”
BackgroundPrefrontal cortical circuits in anxiety and fear: an overview
Chen, Y., Hu, N.-Y., Yang, J., & Gao, T. (2022) · Frontiers of Medicine · doi:10.1007/s11684-022-0941-2 · Cited by 32
Asim, M., Wang, H., Chen, X., & He, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14422 · Cited by 35
Gupta, D., Radhakrishnan, M., Devadoss, T., & Kurhe, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.04.008 · Cited by 31
Chang, H.-Y., Chen, S.-L., Shen, M., Kung, M., Chuang, L., & Chen, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-03747-0 · Cited by 30
Hagihara, H., Ohira, K., & Miyakawa, T. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12048 · Cited by 32
“The dose of FLX used in this study is a clinically relevant dose; 15 mg/kg/d FLX resulted in a range of serum FLX levels in patients taking 20‐80 mg/d of FLX.(19) All animal experiments were approved by the Institutional Animal Care and Use Committee of Fujita Health”
MethodYohn, N. L., Turner, J. R., & Blendy, J. A. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211706 · Cited by 28
“The NIH paradigm is a sensitive measure for potential anxiolytic drugs and anxiogenic effects of withdrawal on both acute and extended drug administration paradigms (Dulawa et al., 2004; Dulawa and Hen, 2005).”
BackgroundZavvari, F., Nahavandi, A., & Shahbazi, A. (2020) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2020.101799 · Cited by 29
Amin, F., Ibrahim, M. A. A., Rizwan-ul-Hasan, S., Khaliq, S., Gabr, G. A., Muhammad, Khan, A., Sidhom, P. A., Tikmani, P., Shawky, A. M., et al. (2022) · Molecules · doi:10.3390/molecules27248658 · Cited by 30
“Both of these targets are similarly included in the antianxiety impacts of medicines that affect the serotonergic system, where 5HT1AR agonists and 5HT2AR antagonists function as anxiolytics [17,18].”
BackgroundAlcohol exacerbates psychosocial stress-induced neuropsychiatric symptoms: Attenuation by geraniol
Ben‐Azu, B., Adebesin, A., Moke, G. E., Ojiokor, V. O., Adebayo, O. G., Jarikre, T. A., Akinluyi, E. T., Olukemi, O. A., Omeiza, N. A., Nkenchor, P., et al. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105748 · Cited by 28
Farhan, M., & Haleem, D. J. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2015.03.006 · Cited by 29
“However, chronic SSRIs treatments are effective in depressed or anxious patients (Barr et al., 1997; Gelfin et al., 1998) as well as in highly emotional animal models (Dulawa et al., 2004; Popa et al., 2008).”
InfluentialSakata, K., Mastin, J. R., Duke, S. M., Vail, M. G., Overacre-Delgoffe, A. E., Dong, B. E., & Jha, S. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12148 · Cited by 29
“Our results of no increased exploratory activity in WT mice agreed with previous reports showing no change or decreases by chronic treatment with Flx (Dulawa et al., 2004; Marlatt et al., 2010), Dul, (Marlatt et al., 2010), or Imi (Schulte-Herbruggen et al., 2012).”
BackgroundMethodResultInfluentialGalyamina, A. G., Kovalenko, I. L., Смагин, Д. А., & Kudryavtseva, N. N. (2017) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-017-0458-3 · Cited by 28
“Increases in movement activity, which are sometimes seen on chronic administration of antidepressants [Dulawa et al., 2004; Plaznik et al., 1994], can probably in our experiments be linked with activation of the noradrenergic system.”
BackgroundKulikova, E. A., Хоцкин, Н. В., Illarionova, N. B., Sorokin, I. E., Bazhenova, E. Y., Kondaurova, E. M., Volcho, K. P., Khomenko, T. M., Salakhutdinov, N. F., Ponimaskin, E. G., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.10.031 · Cited by 29
Xing, B., Zhao, Y., Zhang, H., Dang, Y., Chen, T., Huang, J., & Luo, Q. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.03.007 · Cited by 31
Pang, X., Makinde, E. A., Eze, F. N., & Olatunji, O. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.737764 · Cited by 29
Bond, C. M., Johnson, J. C., Chaudhary, V., McCarthy, E. M., McWhorter, M. L., & Woehrle, N. S. (2019) · Brain Research · doi:10.1016/j.brainres.2019.06.001 · Cited by 28
Wang, Y., Hang, A., Lu, Y., Long, Y., Zan, G., Li, X., Wang, Q., Zhao, Z., He, L., Chi, Z., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.022 · Cited by 30
Popova, D., Ágústsdóttir, A., Lindholm, J., Mazulis, U., Akamine, Y., Castrén, E., & Karpova, N. N. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.04.002 · Cited by 26
“This protocol of chronic fluoxetine administration to adult mice was reported to results in clinically relevant plasma fluoxetine levels (Dulawa et al., 2004; Rantamaki et al., 2007) and to effectively produce behavioral alterations in depression- and anxiety-like behaviors (Karpova et al.”
Brielmaier, J., Senerth, J. M., Silverman, J. L., Matteson, P. G., Millonig, J. H., DiCicco‐Bloom, E., & Crawley, J. N. (2014) · Genes, Brain and Behavior · doi:10.1111/gbb.12115 · Cited by 26
“Desipramine hydrochloride (DMI; 10, 20 and 30 mg/kg/day, salt; Sigma-Aldrich Corporation, St. Louis, MO, USA) was made available ad libitum in the drinking water using procedures previously described (Dulawa et al. 2004; Holick et al. 2008) Vehicle-treated mice received plain (tap) drinking water.”
MethodEffects of oxytocin on serotonin 1B agonist-induced autism-like behavior in mice
Lawson, S. K., Gray, A. C., & Woehrle, N. S. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.07.027 · Cited by 27
Dogra, S., Kumar, A., Umrao, D., Sahasrabuddhe, A. A., & Yadav, P. N. (2016) · Scientific Reports · doi:10.1038/srep33401 · Cited by 27
Åmellem, I., Suresh, S., Chang, C., Tok, S., & Tashiro, A. (2017) · Translational Psychiatry · doi:10.1038/tp.2017.208 · Cited by 28
Payet, J. M., Burnie, E., Sathananthan, N., Russo, A. M., Lawther, A. J., Kent, S., Lowry, C. A., & Hale, M. W. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.06.022 · Cited by 28
Antidepressant-like effect of guanosine involves activation of AMPA receptor and BDNF/TrkB signaling
da Rosa, P. B., Bettio, L. E. B., Neis, V. B., Moretti, M., Kaufmann, F. N., Tavares, M. K., Werle, I., Dalsenter, Y. D. O., Platt, N., Rosado, A. F., et al. (2021) · Purinergic Signalling · doi:10.1007/s11302-021-09779-6 · Cited by 27
Neurological Impairments in Mice Subjected to Irradiation and Chemotherapy
Dey, D., Parihar, V. K., Szabo, G. G., Klein, P., Tran, J. N., Moayyad, J., Ahmed, F., Nguyen, Q.-A., Murry, A., Merriott, D. J., et al. (2020) · Radiation Research · doi:10.1667/rr15540.1 · Cited by 26
Nguyen, T. M. L., Defaix, C., Mendez‐David, I., Tritschler, L., Etting, I., Alvarez, J., Choucha, W., Colle, R., Corruble, E., David, D. J. P., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109357 · Cited by 26
Yang, N., Ren, Z., Zheng, J., Feng, L., Li, D., Gao, K., Zhang, L., Liu, Y., & Zuo, P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.031 · Cited by 27
Herbet, M., Szumełda, I., Piątkowska‐Chmiel, I., Gawrońska‐Grzywacz, M., & Dudka, J. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113185 · Cited by 25
Jedynak, P., Kos, T., Sandi, C., Kaczmarek, L., & Filipkowski, R. K. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.05.009 · Cited by 27
“, 1977a, 1977b) and chronic delivery (e.g., Detke et al., 1997; Dulawa et al., 2004; Holick et al., 2008; Lin and Wang, 2014) as well as in reversal of increased immobility following UCMS (Willner, 2005).”
BackgroundInfluentialAboharb, F., Davoudian, P. A., Shao, L.-X., Liao, C., Rzepka, G. N., Wojtasiewicz, C., Indajang, J., Dibbs, M., Rondeau, J. A., Sherwood, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56850-6 · Cited by 27
Roni, M. A., & Rahman, S. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.10.006 · Cited by 24
“For example, FST climbing and swimming behavior analyses that are claimed to be increased by noradrenergic and serotonergic antidepressants respectively (Cryan et al., 2002; Dulawa et al., 2004) could reveal the effect of drug combination on monoaminergic activity.”
BackgroundFluoxetine Reduces Murine Graft-Versus-Host Disease by Induction of T cell Immunosuppression
Gobin, V., Steendam, K. V., Fevery, S., Tilleman, K., Billiau, A., Denys, D. A. J. P., & Deforce, D. L. D. (2013) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-013-9463-7 · Cited by 26
“In comparison, fluoxetine doses used in mice to obtain an ‘antidepressive’ effect are around 10–18 mg/kg (Dulawa et al. 2004).”
BackgroundTodorović, N., & Filipović, D. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.04.044 · Cited by 25
“Fluoxetine 15 No stress+FLX 280 ± 50 100–700 (Dulawa et al., 2004) CSIS+FLX 203 ± 28”
Effect of Early-Life Fluoxetine on Anxiety-Like Behaviors in BDNF Val66Met Mice
Dincheva, I., Yang, J., Li, A., Marinic, T. E., Freilingsdorf, H., Huang, C., Casey, B. J., Hempstead, B. L., Glatt, C. E., Lee, F. S., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.15121592 · Cited by 25
Flores‐Ramirez, F. J., Garcia-Carachure, I., Sánchez, D. O. M., Gonzalez, C., Castillo, S. A., Arenivar, M. A., Themann, A., Lira, O., Rodriguez, M., Preciado-Piña, J., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118805488 · Cited by 28
“The dose of FLX was selected because it yields a dosage close to 25 mg/kg (Dulawa et al., 2004) – taking into account that females and adolescents metabolize FLX faster than males and/or adults (Anderson, 2005; Hodes et al.”
Zavvari, F., & Nahavandi, A. (2020) · Physiology & Behavior · doi:10.1016/j.physbeh.2020.113140 · Cited by 27
Neuronal tryptophan hydroxylase expression in BALB/cJ and C57Bl/6J mice
Bach, H., Arango, V., Huang, Y., Leong, S., Mann, J. J., & Underwood, M. D. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07379.x · Cited by 24
Lack of stress responses to long-term effects of corticosterone in Caps2 knockout mice
Mishima, Y., Shinoda, Y., Sadakata, T., Kojima, M., Wakana, S., & Furuichi, T. (2015) · Scientific Reports · doi:10.1038/srep08932 · Cited by 28
The failure of anxiolytic therapies in early clinical trials: what needs to be done
Stewart, A., Nguyen, M., Poudel, M. K., Warnick, J. E., Echevarria, D. J., Beaton, E. A., Song, C., & Kalueff, A. V. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1019063 · Cited by 26
“Since most currently available anxiety behavioral tests traditionally target exploratory domains [9,14,24], current preclinical studies of ASDs appear to be generally biased toward such endophenotypic domains.”
BackgroundOrsal, A. S., Blois, S. M., Bermpohl, D., Schaefer, M., & Coquery, N. (2008) · Neuropsychobiology · doi:10.1159/000201718 · Cited by 32
Hussmann, G. P., DeDominicis, K. E., Turner, J. R., Yasuda, R. P., Klehm, J., Forcelli, P. A., Xiao, Y., Richardson, J. R., Sahibzada, N., Wolfe, B. B., et al. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12653 · Cited by 24
“The novelty-induced hypophagia (NIH) test was used as a measurement of anxiety and was carried out as described previously (Turner et al. 2010; Dulawa et al. 2004).”
Zhang, Q., Vuong, H. E., Huang, X., Wang, Y., Brecha, N. C., Pu, M., & Gao, J. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4493-1 · Cited by 23
Ngoupaye, G. T., Yassi, F. B., Bahane, D. A. N., Pahaye, D. B., & Bum, E. N. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110603 · Cited by 24
Liu, B., Ruz‐Maldonado, I., Toczyska, K., Olaniru, O. E., Zariwala, M. G., Hopkins, D., Zhao, M., & Persaud, S. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14791 · Cited by 23
Araki, R., Kita, A., Ago, Y., & Yabe, T. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105682 · Cited by 23
Differential effects of NMDA receptor antagonism on spine density
Ruddy, R. M., Chen, Y., Milenkovic, M., & Ramsey, A. J. (2014) · Synapse · doi:10.1002/syn.21784 · Cited by 25
Heinla, I., Leidmaa, E., Visnapuu, T., Philips, M., & Vasar, E. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.03.024 · Cited by 23
Sargin, D., Chottekalapanda, R. U., Perit, K. E., Yao, V., Chu, D. T., Sparks, D. W., Kalik, S., Power, S. K., Troyanskaya, O. G., Schmidt, E. F., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0473-6 · Cited by 24
The Forced Swimming Test in Mice: A Suitable Model to Study Antidepressants
Hascoët, M., & Bourin, M. (2009) · Neuromethods · doi:10.1007/978-1-60761-303-9_6 · Cited by 26
Ruan, C. S., Zhou, F. H., He, Z. Y., Wang, S., Yang, C., Shen, Y., Guo, Y., Zhao, H., Chen, L., Liu, D., et al. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.02.037 · Cited by 25
Chronic Fluoxetine Treatment of Socially Isolated Rats Modulates Prefrontal Cortex Proteome
Filipović, D., Novak, B., Xiao, J., Yan, Y., Yeoh, K., & Turck, C. W. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.08.011 · Cited by 22
Lin, S., Li, Q., Xu, Z., Chen, Z., Tao, Y., Tong, Y., Wang, T., Chen, S., & Wang, P. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06239-w · Cited by 23
“The dosage of fluoxetine was according to previous literatures (Christiansen et al. 2011; Dulawa et al. 2004).”
MethodЦейликман, В. Э., Tseilikman, O. B., Karpenko, M. N., Traktirov, D. S., Obukhova, D. A., Shatilov, V. A., Zhukov, M. S., Валерьевич, М. Г., Yegorov, O. N., Aristov, M. R., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12112455 · Cited by 24
Littrell, J. L. (2012) · Frontiers in Psychology · doi:10.3389/fpsyg.2012.00297 · Cited by 25
“Treatment with antidepressants will decrease immobility in a forced swim test, will increase exploration in a novel environment, and will preclude the decrement in food consumption produced by a novel environment (Dulawa et al., 2004).”
BackgroundDeng, W., & Gage, F. H. (2015) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2015.00034 · Cited by 27
“For the novelty-induced hypophagia (NIH) test, we followed the procedure described by Dulawa and colleagues with some modifications (Dulawa et al., 2004).”
MethodJohnson, Z. V., Moore, E. C., Wong, R. Y., Godwin, J., Streelman, J. T., & Roberts, R. B. (2019) · Animal Behaviour · doi:10.1016/j.anbehav.2019.11.006 · Cited by 22
Sakhaie, N., Sadegzadeh, F., Dehghany, R., Adak, O., & Saadati, H. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.06.009 · Cited by 23
Psychotropic and Neurotropic Activity
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_6 · Cited by 24
Studies of Depression-Related States in Animal Models of Parkinsonism
Schintu, N., Zhang, X., & Svenningsson, P. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-12076 · Cited by 22
“are sensitive to chronic, but not acute, antidepressant treatments [19].”
BackgroundWang, Q., Shao, F., & Wang, W. (2018) · Neural Plasticity · doi:10.1155/2018/9870985 · Cited by 23
“In addition, it has been shown that compared with acute antidepressant treatment, chronic antidepressant treatment has better outcomes for the amelioration of cognitive dysfunctions [11] and similar effects on emotional symptoms [12].”
BackgroundFeng, M., Crowley, N. A., Patel, A., Guo, Y., Bugni, S. E., & Luscher, B. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.03.003 · Cited by 20
“The Forced Swim Test (FST) was used as a rodent behavioral assay with predictive validity for antidepressant drug activity (Dulawa et al., 2004; Lucki, 1997).”
MethodBen‐Azu, B., Chidebe, E. O., Toloyai, P.-E. Y., Annafi, O. S., Oritsemuelebi, B., Asiwe, J. N., Moke, E. G., Ajayi, A. M., Chukwuebuka, N. B., Onuelu, J. E., et al. (2024) · Clinical Traditional Medicine and Pharmacology · doi:10.1016/j.ctmp.2024.200148 · Cited by 22
Marrero, M. G., Dado-Senn, B., Field, S. L., da Silva, D. R., Skibiel, A. L., & Laporta, J. (2019) · Domestic Animal Endocrinology · doi:10.1016/j.domaniend.2019.04.007 · Cited by 20
“Fluoxetine administration to mice and zebrafish resulted in reduced social stress and aggressive behavior, respectively [37,38].”
BackgroundNakamura, Y., Kitamura, Y., Sumiyoshi, Y., Naito, N., Kan, S., Ushio, S., Miyazaki, I., Asanuma, M., & Sendo, T. (2018) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2018.10.001 · Cited by 20
Jang, D., Lee, H.-J., Lee, K., Kim, K.-R., Won, R., Lee, S. E., & Shim, I. (2019) · BioMed Research International · doi:10.1155/2019/5705232 · Cited by 20
“PC-treated group exhibited significant decrease of immobility time in TST and FST compared to the control, consistentwith previous finding [27].”
ResultNiwa, M., Lockhart, S., Wood, D. J., Yang, K., de Oliveira, J. F., Kin, K., Ahmed, A., Wand, G. S., Kano, S., Payne, J. L., et al. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00217-1 · Cited by 21
“Serum fluoxetine concentrations at 18 mg kg day –1 in mice have been reported to be toward the upper end of the plasma concentration range seen in patients taking 20–80 mg day –1 of Prozac 83 .”
Corticosterone Facilitates Fluoxetine-Induced Neuronal Plasticity in the Hippocampus
Kobayashi, K., Ikeda, Y., Asada, M., Inagaki, H., Kawada, T., & Suzuki, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063662 · Cited by 20
“However, these effects were not reliably induced at the suggested optimal dose range for mice (10 to 18 mg/kg/day) that gives rise to plasma drug levels comparable to those in patients taking chronic fluoxetine [9] and required higher doses of treatment, which raises a possibility that these are related to overdose ef…”
BackgroundResult
Metadata
- Authors
- Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R.
- Affiliations
- Columbia University (US)
- Venue
- Neuropsychopharmacology
- Published
- 2004-04-07
- Volume
- 29
- Issue
- 7
- Pages
- 1321-1330
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1987972424
- Cited by
- 671
- References
- 50
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 27 · 2023: 28 · 2022: 32 · 2021: 32 · 2020: 31 · 2019: 51 · 2018: 31 · 2017: 42 · 2016: 34 · 2015: 42 · 2014: 41 · 2013: 44 · 2012: 28
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression (MH068542-1)
- National Institutes of Health (5r01da009862-08, 5f32mh065791-02)
- National Institute of Mental Health (F32-MH65791-01A1, P50MH050733, P50-MH50733, R01 MH068542-1, R01MH068542)
- National Institute on Drug Abuse (R01 DA09862)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- fluoxetine, chronic antidepressant treatment, anxiety, depression, selective serotonin reuptake inhibitors, inbred mouse strains, BALB/c mice, forced swim test, novelty-induced hypophagia, locomotor activity, antidepressant sensitivity
- MeSH terms
- Analysis of Variance, Animals, Anxiety, Behavior, Animal, Depression, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Administration Schedule, Exploratory Behavior, Fluoxetine, Immobilization, Male, Mice, Inbred Strains, Motor Activity, Reaction Time, Species Specificity, Swimming, Time Factors, Selective Serotonin Reuptake Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.